Key result
Anticoagulant therapy for cancer patients with incident thrombosis consisted predominantly of LMWHs (57%), VKAs (24%), and DOACs (17%), with an average prescription duration of 4.5 months.
Why the study?
The study aimed to investigate real-world anticoagulation treatment for cancer patients with thrombosis in the outpatient sector of Germany.
Observational (n=7,313)
In Germany, the duration of anticoagulation for cancer-associated thrombosis aligns with guidelines, but the choice of agent often deviates from contemporary recommendations.
Authors
No takes yet. Share an insight, caveat, or question.
Duration aligns with guidelines but LMWH predominates over DOACs in German cancer thrombosis care; leaves open outcome impact.
Riess et al. (2021) conducted an observational in Cancer with incident thrombosis (n=7,313). Anticoagulant drugs (LMWHs, VKAs, DOACs) was evaluated on Anticoagulant use (type and duration). Anticoagulant therapy for cancer patients with incident thrombosis consisted predominantly of LMWHs (57%), VKAs (24%), and DOACs (17%), with an average prescription duration of 4.5 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: